Updated results of the first 20 patients with B cell malignancies (5 CLL, 10 B-NHL, and 5 B-ALL) that progressed after allo-HSCT who received allogeneic T cells transduced with CAR targeting CD19 were reported by Brudno et al. (2016). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.